Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00107822 · ClinicalTrials.gov registry record · Phase 3
Safety Study of S-Caine Peel (Skin Numbing Cream) Before a Painful Dermatologic Procedure in Children
A Phase 3 study, sponsored by ZARS Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 80
- Enrollment target
NCT00107822 is a Phase 3 study that has completed, run by ZARS Pharma. The registered enrollment target is 80 participants.
The verdict
NCT00107822, a Phase 3 study, has completed, sponsored by ZARS Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 80 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of one treatment of S-Caine™ Peel (skin numbing cream) applied on healthy skin before a painful dermatologic procedure in children. This study will also evaluate how well the S-Caine™ Peel eases the pain of the procedure.
Interventions
- DRUG S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2005-04 |
| Est. Completion | 2005-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00107822
The ClinicalTrials.gov registry entry for NCT00107822 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ZARS Pharma, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%) is the first listed.
NCT00107822 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00107822 about?
NCT00107822 is a clinical study titled "Safety Study of S-Caine Peel (Skin Numbing Cream) Before a Painful Dermatologic Procedure in Children". The purpose of this study is to evaluate the safety of one treatment of S-Caine™ Peel (skin numbing cream) applied on healthy skin before a painful dermatologic procedure in children. This study will also evaluate how well the S-Caine™ Peel eases the pain of the procedure.
What is the current status of trial NCT00107822?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 80 participants. The study started on 2005-04. Estimated completion is 2005-05.
What interventions are being tested in trial NCT00107822?
The interventions under investigation include: S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%) (DRUG).
Who is sponsoring clinical trial NCT00107822?
This trial is sponsored by ZARS Pharma, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.